论文部分内容阅读
采用酶联免疫吸附法（ELISA）对30例肺癌患者和30例健康者血清可溶性白细胞介素2受体（SIL－2R）和白细胞介素6（IL－6）水平进行观察。结果显示，肺癌患者血清SIL－2R和IL－6水平明显升高，和正常对照组比较，差异非常显著（P＜0．01）。同时肺癌患者经化疗后血清SIL－2R和IL－6水平随病情恶化而升高、病情缓解而下降，治疗前后比较有非常显著性差异（P＜0．01）。提示肺癌患者存有免疫调控功能紊乱和细胞免疫功能低下。检测血清SIL－2R和IL－6可作为肺癌患者诊断的参考指标，治疗、预后的监测指标。
Serum soluble interleukin 2 receptor (SIL-2R) and interleukin 6 (IL-6) levels were observed in 30 lung cancer patients and 30 healthy subjects by enzyme-linked immunosorbent assay (ELISA). The results showed that the serum levels of SIL-2R and IL-6 in patients with lung cancer were significantly higher than those in normal controls (P<0.01). At the same time, the serum levels of SIL-2R and IL-6 in patients with lung cancer were increased with the worsening of the disease and the disease was reduced after chemotherapy. There was a very significant difference between before and after treatment (P<0.01). It is suggested that lung cancer patients have immunoregulatory dysfunction and low cellular immunity. Detection of serum SIL-2R and IL-6 can be used as a reference index for the diagnosis of lung cancer patients, and a monitoring indicator for treatment and prognosis.